We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

561 hedge funds and large institutions have $26B invested in Alexion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 220 increasing their positions, 204 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 61

2% more funds holding

Funds holding: 548 → 561 (+13)

8% more repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 204

2% more call options, than puts

Call options by funds: $261M | Put options by funds: $257M

3% less capital invested

Capital invested by funds: $26.9B → $26B (-$932M)

29% less funds holding in top 10

Funds holding in top 10: 24 → 17 (-7)

Holders
561
Holders Change
+13
Holders Change %
+2.37%
% of All Funds
13.97%
Holding in Top 10
17
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-29.17%
% of All Funds
0.42%
New
84
Increased
220
Reduced
204
Closed
61
Calls
$261M
Puts
$257M
Net Calls
+$4.33M
Net Calls Change
+$22.1M

Top Buyers

1
BlackRock
BlackRock
New York
+$2.32B
2
JP Morgan Chase
JP Morgan Chase
New York
+$175M
3
Jennison Associates
Jennison Associates
New York
+$174M
4
Norges Bank
Norges Bank
Norway
+$128M
5
PI
Putnam Investments
Massachusetts
+$122M

Top Sellers

1
Capital Research Global Investors
Capital Research Global Investors
California
-$922M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
-$275M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$232M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$150M
5
WRF
Waddell & Reed Financial
Kansas
-$134M
Name Holding Trade Value Shares
Change 		Change in
Stake
SHCM
51
Sachem Head Capital Management
New York
$77M -$38.7M -300,000 -32%
Sumitomo Mitsui Trust Group
52
Sumitomo Mitsui Trust Group
Japan
$75M -$191K -1,482 -0.2%
FAM
53
Fred Alger Management
New York
$74.5M -$15.5M -120,090 -16%
Morgan Stanley
54
Morgan Stanley
New York
$71M +$39.9M +309,299 +112%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$70M -$412K -3,195 -0.6%
CS
56
Credit Suisse
Switzerland
$69M +$11.1M +86,141 +18%
Federated Hermes
57
Federated Hermes
Pennsylvania
$68.4M -$1.83M -14,196 -2%
MWNA
58
Marshall Wace North America
New York
$65.2M +$69.5M +539,002 New
SO
59
STRS Ohio
Ohio
$65M -$8.8M -68,241 -11%
RSCM
60
Rock Springs Capital Management
Maryland
$55.4M -$1.04M -8,100 -2%
Mitsubishi UFJ Trust & Banking
61
Mitsubishi UFJ Trust & Banking
Japan
$54.1M +$12.6K +98 +0%
California Public Employees Retirement System
62
California Public Employees Retirement System
California
$53.2M -$2.36M -18,300 -4%
PC
63
Polar Capital
United Kingdom
$53.1M -$2.95M -22,916 -5%
California State Teachers Retirement System (CalSTRS)
64
California State Teachers Retirement System (CalSTRS)
California
$52.4M -$2.57M -19,900 -4%
GC
65
Guggenheim Capital
Illinois
$52.2M +$3.63M +28,129 +7%
Two Sigma Investments
66
Two Sigma Investments
New York
$52.1M +$55.4M +429,420 New
TA
67
Teachers Advisors
New York
$51.2M +$1.57M +12,179 +3%
Two Sigma Advisers
68
Two Sigma Advisers
New York
$49.6M +$47.9M +371,662 +1,002%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$46.9M +$1.33M +10,282 +3%
CC
70
Carlson Capital
Texas
$45.4M +$34.8M +269,883 +258%
New York State Teachers Retirement System (NYSTRS)
71
New York State Teachers Retirement System (NYSTRS)
New York
$45.2M +$751K +5,823 +2%
Renaissance Technologies
72
Renaissance Technologies
New York
$43.8M +$46.5M +360,942 New
TD Asset Management
73
TD Asset Management
Ontario, Canada
$43.7M -$292K -2,265 -0.6%
Westfield Capital Management
74
Westfield Capital Management
Massachusetts
$43.6M +$46.3M +359,212 New
MVP
75
Miller Value Partners
Florida
$43.5M +$33.4M +258,990 +260%
1 2
3
4 5

ALXN Hedge Fund Activity: Q1 2017 in Review

561 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2017, worth a combined $26B — down 3.5% from $26.9B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new ALXN positions and 61 closed out — a net gain of 23 holders — while 220 added to existing stakes and 204 trimmed.

The largest buyer was BlackRock, adding an estimated $2.32B. The largest seller was Capital Research Global Investors, cutting an estimated $922M.

  • 561 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2017, up from 548 in Q4 2016.
  • Funds reported $26B of Alexion Pharmaceuticals stock for Q1 2017, down 3.5% quarter-over-quarter.
  • 84 funds opened new Alexion Pharmaceuticals positions in Q1 2017 and 61 closed out, a net change of +23 holders.
  • The largest Alexion Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.32B added.
  • The largest Alexion Pharmaceuticals seller in Q1 2017 was Capital Research Global Investors, an estimated $922M sold.

Based on aggregated 13F filings for Q1 2017.